EOM Pharmaceuticals Holdings, Inc. IMUC
OTC PK
| 09/30/2022 | 03/31/2022 | 12/31/2021 | 09/30/2021 | ||
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | |
| Total Other Revenue | -- | -- | -- | -- | |
| Total Revenue | -- | -- | -- | -- | |
| Cost of Revenue | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | |
| SG&A Expenses | 81.79% | -17.52% | -90.51% | 17.61% | |
| Depreciation & Amortization | -- | -- | -- | -- | |
| Other Operating Expenses | -- | -- | -- | -- | |
| Total Operating Expenses | 34.34% | -20.99% | -69.25% | 20.40% | |
| Operating Income | -34.34% | 20.99% | 69.25% | -20.40% | |
| Income Before Tax | -48.67% | 22.01% | -116.63% | -21.73% | |
| Income Tax Expenses | -- | -- | -- | -- | |
| Earnings from Continuing Operations | -48.67% | 22.01% | -116.63% | -21.73% | |
| Earnings from Discontinued Operations | -- | -- | -- | -- | |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
| Minority Interest in Earnings | -- | -- | -- | -- | |
| Net Income | -48.67% | 22.01% | -116.63% | -21.73% | |
| EBIT | -34.34% | 20.99% | 69.25% | -20.40% | |
| EBITDA | -- | -- | -- | -- | |
| EPS Basic | 34.95% | 69.06% | -63.47% | -35.37% | |
| Normalized Basic EPS | 34.38% | 69.29% | 76.79% | -34.62% | |
| EPS Diluted | 2.91% | 55.16% | -67.93% | -35.37% | |
| Normalized Diluted EPS | 34.38% | 69.29% | 76.79% | -34.62% | |
| Average Basic Shares Outstanding | 126.54% | 151.29% | 32.48% | -9.85% | |
| Average Diluted Shares Outstanding | 126.54% | 151.29% | 32.48% | -9.85% | |
| Dividend Per Share | -- | -- | -- | -- | |
| Payout Ratio | -- | -- | -- | -- | |